FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
This article was originally published in The Pink Sheet Daily
Executive Summary
Heading into an Antiviral Products Advisory Committee review April 28, FDA briefing documents indicate some strengths for Vertex's HCV drug over Merck's boceprevir.